TY - JOUR
T1 - Primary Care-Based Interventions to Prevent Illicit Drug Use in Children, Adolescents, and Young Adults
T2 - US Preventive Services Task Force Recommendation Statement
AU - Krist, Alex H.
AU - Davidson, Karina W.
AU - Mangione, Carol M.
AU - Barry, Michael J.
AU - Cabana, Michael
AU - Caughey, Aaron B.
AU - Donahue, Katrina
AU - Doubeni, Chyke A.
AU - Epling, John W.
AU - Kubik, Martha
AU - Ogedegbe, Gbenga
AU - Pbert, Lori
AU - Silverstein, Michael
AU - Simon, Melissa A.
AU - Tseng, Chien Wen
AU - Wong, John B.
N1 - Publisher Copyright:
© 2020 American Medical Association. All rights reserved.
PY - 2020/5/26
Y1 - 2020/5/26
N2 - Importance: In 2017, an estimated 7.9% of persons aged 12 to 17 years reported illicit drug use in the past month, and an estimated 50% of adolescents in the US had used an illicit drug by the time they graduated from high school. Young adults aged 18 to 25 years have a higher rate of current illicit drug use, with an estimated 23.2% currently using illicit drugs. Illicit drug use is associated with many negative health, social, and economic consequences and is a significant contributor to 3 of the leading causes of death among young persons (aged 10-24 years): unintentional injuries including motor vehicle crashes, suicide, and homicide. Objective: To update its 2014 recommendation, the USPSTF commissioned a review of the evidence on the potential benefits and harms of interventions to prevent illicit drug use in children, adolescents, and young adults. Population: This recommendation applies to children (11 years and younger), adolescents (aged 12-17 years), and young adults (aged 18-25 years), including pregnant persons. Evidence Assessment: Because of limited and inadequate evidence, the USPSTF concludes that the benefits and harms of primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults are uncertain and that the evidence is insufficient to assess the balance of benefits and harms. More research is needed. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care-based behavioral counseling interventions to prevent illicit drug use, including nonmedical use of prescription drugs, in children, adolescents, and young adults. (I statement).
AB - Importance: In 2017, an estimated 7.9% of persons aged 12 to 17 years reported illicit drug use in the past month, and an estimated 50% of adolescents in the US had used an illicit drug by the time they graduated from high school. Young adults aged 18 to 25 years have a higher rate of current illicit drug use, with an estimated 23.2% currently using illicit drugs. Illicit drug use is associated with many negative health, social, and economic consequences and is a significant contributor to 3 of the leading causes of death among young persons (aged 10-24 years): unintentional injuries including motor vehicle crashes, suicide, and homicide. Objective: To update its 2014 recommendation, the USPSTF commissioned a review of the evidence on the potential benefits and harms of interventions to prevent illicit drug use in children, adolescents, and young adults. Population: This recommendation applies to children (11 years and younger), adolescents (aged 12-17 years), and young adults (aged 18-25 years), including pregnant persons. Evidence Assessment: Because of limited and inadequate evidence, the USPSTF concludes that the benefits and harms of primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults are uncertain and that the evidence is insufficient to assess the balance of benefits and harms. More research is needed. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care-based behavioral counseling interventions to prevent illicit drug use, including nonmedical use of prescription drugs, in children, adolescents, and young adults. (I statement).
UR - http://www.scopus.com/inward/record.url?scp=85085325222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085325222&partnerID=8YFLogxK
U2 - 10.1001/jama.2020.6774
DO - 10.1001/jama.2020.6774
M3 - Article
C2 - 32453374
AN - SCOPUS:85085325222
SN - 0098-7484
VL - 323
SP - 2060
EP - 2066
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 20
ER -